Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

BACKGROUND: After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). We aim to analyse LABA- and ICS-re...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Pulm Med
Auteurs principaux: Rottenkolber, Marietta, Fischer, Rainald, Ibáñez, Luisa, Fortuny, Joan, Reynolds, Robert, Amelio, Justyna, Gerlach, Roman, Tauscher, Martin, Thürmann, Petra, Hasford, Joerg, Schmiedl, Sven
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2015
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4428117/
https://ncbi.nlm.nih.gov/pubmed/25943421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-015-0051-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires